›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:TruSight Oncology 500 Assay
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
IlluminaType:
Laboratory Developed Test
Related tests:
TruSight Oncology 500 is a next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling of tumor samples. It supports identification of all relevant DNA and RNA variants implicated in various solid tumor types.
In addition, it accurately measures key current immuno-oncology biomarkers: microsatellite instability (MSI) and tumor mutational burden (TMB). It consolidate Multiple Biomarker Assays into One:
Pan-cancer biomarker content aligned with key guidelines and clinical trials. DNA + RNA assay targeting 523 genes for assessment of all DNA and RNA variant types, plus MSI and TMB. Increase chances of finding a positive biomarker by moving from individual biomarker assays to a single comprehensive NGS assay.
Cancer:
Bladder Cancer, Breast Cancer, Colon Cancer, Gastric Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Sarcoma
Gene:
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CTNNB1 (Catenin (cadherin-associated protein), beta 1)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CTNNB1 (Catenin (cadherin-associated protein), beta 1), EGFR (Epidermal growth factor receptor), ETV6 (ETS Variant Transcription Factor 6), EWSR1 (EWS RNA Binding Protein 1), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FOXO1 (Forkhead box O1), GNA11 (G Protein Subunit Alpha 11), GNAQ (G Protein Subunit Alpha Q), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MDM2 (E3 ubiquitin protein ligase), MET (MET proto-oncogene, receptor tyrosine kinase), MLH1 (MutL homolog 1), MSH2 (MutS Homolog 2), MSH6 (MutS homolog 6), MSI (Microsatellite instability), NF1 (Neurofibromin 1), NRAS (Neuroblastoma RAS viral oncogene homolog), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), PMS2 (PMS1 protein homolog 2), PTEN (Phosphatase and tensin homolog), RET (Ret Proto-Oncogene), SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B), SDHC (Succinate Dehydrogenase Complex Subunit C), TMB (Tumor Mutational Burden), TP53 (Tumor protein P53), TSC1 (TSC complex subunit 1), WT1 (WT1 Transcription Factor)
Method:
Next-Generation Sequencing (NGS)
